Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

had cleared the Libre Rio, a new over-the-counter (OTC) CGM option for type 2 diabetes patients who do not use insulin (the FreeStyle Libre targets insulin and non-insulin users). A simpler ...

Abbott launched an over-the-counter continuous glucose monitoring system, Lingo, for adults not on insulin -- the second such ...

A parenting expert has given five top tips to help parents adjust to a quieter household as millions of students prepare to ...

The Food and Drug Administration cleared Abbott’s Freestyle Libre 2 and 3 for integration with AID systems in March 2023. Earlier this year, Abbott integrated its FreeStyle Libre 2 Plus sensor with ...

Thursday, Abbott Laboratories ABT said it is recalling some FreeStyle Libre 3 sensors after finding ... Continuous Glucose Monitoring To Type 2 Diabetes Patients. This recall involves removing ...

Some better-ranked stocks in the broader medical space are TransMedix Group TMDX, Veracyte VCYT and Boston Scientific BSX. While TransMedix Group and Veracyte currently sport a Zacks Rank #1 (Strong ...

Abbott’s FreeStyle Libre products have more than six million users who have type 1 or type 2 diabetes. She added that the collaboration provides people with diabetes expanded choice, calling it ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...